The CEO of Moderna Inc. (NASDAQ: MRNA) showed optimism for the company in a recent interview for Squawk Box on CNBC, foreseeing between $6 billion to $8 billion in sales in 2023, as their COVID-19 booster got approved by the FDA on September 11.
“It is already in trucks. I’m going to get mine on Monday.
We think it’s going to be like a flu shot. Covid is not going away.”
— Stephane Bancel, Moderna CEO for Squawk Box
Bancel has a strong opinion on COVID boosters being something recurrent, that everyone should take again and again. Which explains Moderna’s strategy and investments in this product.
Picks for you
However, the company’s development is not only limited by COVID-19, but also to further research on how mRNA works, and how to use technology to improve an individual’s immune system to prevent other diseases, such as cancer, as explained in the video.
“We designed a product that will teach your immune system to exactly look for the mutation you have because cancer is a mutation of DNA [using the mRNA technology]”
— Stephane Bancel, Moderna CEO for Squawk Box
MRNA chart analysis
Moderna stocks had a great year in 2021, with the Covid reaching its peak in infections worldwide, and boosters being approved by regulators. In this context, MRNA went from $64 per share in 2020, to the stock’s all-time high one year later, in September 2021, for $426.40 per share — registering over 565% in gains due to the pandemic.
Currently, MRNA is trading at $105.24 per share.
Notably, the company is projecting $25 billion investments in research and development of new products from 2024 to 2028, while also expecting around $10 billion to $15 billion in sales by 2028, from these newly developed products.
Watch the interview with Moderna CEO on CNBC:
Buy stocks now with Interactive Brokers – the most advanced investment platform
Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.
